节点文献

川参通联合α1A受体阻滞剂治疗Ⅲ型前列腺炎的临床研究

Clinical Study on Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndromes by Chuanshentong and Alpha-1A Receptor Blockader

【作者】 洪国灿

【导师】 李惠长;

【作者基本信息】 福建中医学院 , 中西医结合临床, 2009, 硕士

【摘要】 目的:评价川参通注射液联合α1A受体阻滞剂治疗Ⅲ型前列腺炎血瘀证的临床疗效。方法:本项研究将60例符合纳入标准的患者分为随机分为两组:川参通组(n=30),经会阴部前列腺局部注射川参通注射液及口服盐酸坦洛新缓释胶囊;对照组(n=30),口服盐酸坦洛新缓释胶囊;临床治疗18天。于治疗前、治疗后、停药后1个月测定慢性前列腺炎症状指数评分(NIH-CPSI)、慢性前列腺炎中医辨证评分、最大尿流率及残余尿量,并对上述结果进行统计学分析。结果:1、川参通组治疗后及停药后1个月疗效均优于对照组;川参通组停药后1个月较治疗后疗效无明显变化;但对照组停药后1个月较治疗后疗效明显降低。2、川参通组及对照组在治疗后及停药后1个月均能较好的改善患者的NIH-CPSI总积分、疼痛积分、尿道症状积分、生活质量评分、中医辨证评分、最大尿流率、残余尿量,但川参通组改善情况明显优于对照组。3、川参通组NIH-CPSI总积分、疼痛积分、尿道症状积分、生活质量评分、中医辨证评分、最大尿流率、残余尿量停药后1个月与治疗后比较均无明显改变;而对照组停药后1个月较治疗后明显恶化。结论:川参通注射液联合α1A受体阻滞剂是治疗Ⅲ型前列腺炎的有效方法,在改善患者临床症状、生活质量及下尿路梗阻上具有独特的优势,并能有效延缓或减少病情的复发。

【Abstract】 Objective:To evaluate the efficacy that Chuanshentong and alpha-1A receptor blockader treat Chronic Prostatitis/Chronic Pelvic Pain Syndromes with syndrome types of Xueyu.Methods:The patients who would be consistent with the inclusion criteria were divided into two groups randomly:Chuanshentong group(n=30),injected Chuanshentong injection into the prostate by perineal and took tamsulosin hydrochloride release capsules for 18 days. Control group(n=30),took tamsulosin hydrochloride release capsules for 18 days.Every group was examined with the National Institutes of Health chronic prostatitis symptom index(NIH-CPSI),chronic prostatitis Traditional Chinese Medicine(TCM) score,maximum urinary flow rate and residual urine volume at pre-treatment,post-treatment and one month drug off-application.These results were statistically analyzed.Result:1.The efficacy of Chuanshentong group were better than the efficacy of control group at post-treatment and one month drug off-application.The efficacy of Chuanshentong group at one month drug off-application was not significantly changed compared with post-treatment.But the efficacy of Control group was decreased significantly.2.The Chuanshentong group and the control group had able to improve the patient’s NIH-CPSI total score,pain score,urinary tract symptom score,quality of life score,TCM score, maximum flow rate,residual urine volume at post-treatment and one month drug off-application.However,Chuanshentong group to improve the situation was better than the control group.3.It was no significantly change in the NIH-CPSI total score,pain score, urinary tract symptom score,quality of life score,TCM score,maximum urinary flow rate, residual urine volume of Chuanshentong group between the period of one month drug off-application and post-treatment,but the control group was aggravation.Conclusion:It is a effective way to treat CP/CPPS with chuanshentong and alpha-1A receptor blockader.It has unique advantages to improve the clinical symptoms,quality of life and on lower urinary tract obstruction,and can effectively delay or reduce the pathogenetic condition relapse.

节点文献中: 

本文链接的文献网络图示:

本文的引文网络